Who we are
For over 30 years, TIB Molbiol is leading the global biotech market by supplying high-quality reagents and developing reliable, rapid real-time PCR-based tests to provide essential answers for laboratories and patients.
TIB Molbiol provides PCR kits and custom oligonucleotide synthesis for research, diagnostics and environmental analysis. Specializing in molecular diagnostics, we offer a wide range of assays for infectious diseases, genetic diseases and custom kits for research. In December 2021, TIB Molbiol was acquired by Roche, further strengthening our ability to provide innovative diagnostic solutions and enhance our commitment to advancing healthcare worldwide.
Based in Berlin, Germany, TIB Molbiol began in 1990 as a small business specializing in the production of oligonucleotides. Today, operating from a 4,000-square-meter facility, TIB Molbiol has expanded its presence to the USA and collaborates globally through Roche affiliates, enhancing our capacity to swiftly address biological threats.
We and Roche
TIB Molbiol, based in Berlin, is part of the Roche family since 2021. As a subsidiary of the Roche Group, we continue to see ourselves as a driver of innovation in the research and development of diagnostic solutions in the fight against diseases.
The acquisition significantly expands Roche’s portfolio, which includes over 70 CE-IVD assays and more than 250 research-use-only assays for the LightCycler® and cobas® PCR systems, by incorporating our extensive range of molecular diagnostics, including tests for SARS-CoV-2 variants. With our assays now available on Roche’s LightCycler®, the collaboration builds on a 20-year partnership that has enabled rapid responses to biological threats such as SARS, anthrax, H5N1, MERS, H1N1, Ebola, Zika, and SARS-CoV-2.
Together with Roche, we achieved a significant milestone in January 2020 by launching the first research test for SARS-CoV-2, merely days after the virus's genetic sequence was made available. This swift development underscored our shared commitment to addressing emergent public health threats with urgency and precision. Through our partnership, we have established the broadest portfolio of PCR-based tests available on the market, encompassing a wide range of diagnostic solutions. This extensive portfolio not only highlights our innovative prowess but also ensures that healthcare providers globally have access to reliable and versatile testing options to manage and mitigate the spread of infectious diseases effectively.
Our DNA
is all about developing reliable real-time PCR based tests at high speed and ensuring that laboratories and patients get the answers they need - without fuss or frippery, just the Berlin way. In doing so, we value close customer relationships and teamwork with local scientific experts.
Our Vision
is to continue to be the first responder to new infectious disease outbreaks, ensuring rapid, scalable, and automated diagnostic solutions are accessible worldwide. Renowned for our exceptional speed in developing assays for emerging infectious diseases, we have consistently demonstrated the expertise and agility necessary to respond to urgent public health threats. We will continue to expand our product portfolio for platforms like LightCycler®, cobas® and Digital LightCycler®. We are also committed to enabling medical research as a supplier for scalable custom oligonucleotides and tailor made PCR kits.
How it all
began
Founded in 1990, the company began with a focus on custom synthesis of oligonucleotides, a critical component in a variety of applications. Initially specializing in producing these short DNA or RNA sequences for specific customer needs, our oligonucleotides have been instrumental in supporting basic scientific research, environmental analysis, and quality control across diverse industries. Over time, our expertise expanded to include vital applications in medical diagnostics, where these oligonucleotides play a key role in detecting genetic mutations, pathogens, and other biomarkers, helping advance both research and clinical practices.
